Open

Do GIP/GLP-1 & amylin agonists cause more adverse events & safety versus placebo?

Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →

Where the evidence stands

Unlikely. So far, the results disagree.

NoUnsureYes
Belief
0.00 (range 0.00–0.55)
Trials for
0
Trials against
3
Inconclusive
1

Already under way

No registered trial that could settle this is recruiting or active.

The evidence so far

Registered trials
109
With posted results
13
Published papers
9

Of 4 decided analyses: 2 favor gip/glp-1 & amylin agonists, 2 find no difference, 0 favor the comparator.

Papers

Trials

See every trial in the evidence map →